



Roivant Discovery and Edelris Enter into Drug Discovery Research Collaboration

Boston (USA) and Lyon (France), November 16 2021. Roivant Discovery, the drug discovery engine of Roivant Sciences ("Roivant"), and Edelris are pleased to announce that they have entered into a Research Collaboration to identify small molecule ligands against a target of interest for Roivant.

Edelris will apply EDEN, the Edelris **D**iscovery **E**ngine platform, built upon a unique and proprietary small molecules collection originating from the Keymical Space™ and coupled with efficient Affinity Selection-Mass Spectrometry (AS-MS) screening technologies.

"The integration of our leading computational physics-based platform for *in silico* drug design and our experimental engine is well suited to take advantage of the exciting AS-MS capabilities and unique screening deck of Edelris. This will enable the rapid design of molecules with high precision and fidelity to address challenging targets for diseases with high unmet need," said Dr. Eric Valeur, VP of Drug Discovery.

"We are thrilled to initiate discovery efforts on behalf of Roivant, on a very challenging target. Roivant's bold vision and entrepreneur spirit fits well with Edelris creativity and client-oriented mindset. The combination of our proprietary 2M natural product-like collection and our state-of-the-art AS-MS screening technologies is uniquely suited for the selection of chemically tractable, lead-like and patentable chemical matter against this undisclosed biological target," said Dr. Jean-Yves Ortholand, CEO of Edelris.

Under the terms of the Agreement, Edelris will be eligible for several payments as the project progresses, in addition to license fees.